These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24649958)

  • 1. Early repositioning through compound set enrichment analysis: a knowledge-recycling strategy.
    Temesi G; Bolgár B; Arany A; Szalai C; Antal P; Mátyus P
    Future Med Chem; 2014 Apr; 6(5):563-75. PubMed ID: 24649958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.
    Tan F; Yang R; Xu X; Chen X; Wang Y; Ma H; Liu X; Wu X; Chen Y; Liu L; Jia X
    Mol Biosyst; 2014 May; 10(5):1126-38. PubMed ID: 24603772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico drug repositioning: from large-scale transcriptome data to therapeutics.
    Kwon OS; Kim W; Cha HJ; Lee H
    Arch Pharm Res; 2019 Oct; 42(10):879-889. PubMed ID: 31482491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating LINCS Data to Evaluate Cancer Transcriptome Modifying Potential of Small-molecule Compounds for Drug Repositioning.
    Zhao Y; Liu Y; Bai H
    Comb Chem High Throughput Screen; 2021; 24(9):1340-1350. PubMed ID: 33109034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network.
    Jadamba E; Shin M
    Biomed Res Int; 2016; 2016():7147039. PubMed ID: 28127549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.
    Emon MA; Domingo-Fernández D; Hoyt CT; Hofmann-Apitius M
    BMC Bioinformatics; 2020 Jun; 21(1):231. PubMed ID: 32503412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data.
    Iwata H; Sawada R; Mizutani S; Yamanishi Y
    J Chem Inf Model; 2015 Feb; 55(2):446-59. PubMed ID: 25602292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Connections in pharmacology: innovation serving translational medicine.
    Montero-Melendez T; Perretti M
    Drug Discov Today; 2014 Jul; 19(7):820-3. PubMed ID: 24316023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico drug repositioning: what we need to know.
    Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
    Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance.
    Liu L
    J Med Chem; 2014 Apr; 57(7):2843-4. PubMed ID: 24654838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-aspect candidates for repositioning: data fusion methods using heterogeneous information sources.
    Arany Á; Bolgár B; Balogh B; Antal P; Mátyus P
    Curr Med Chem; 2013; 20(1):95-107. PubMed ID: 23210850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico repositioning of approved drugs for rare and neglected diseases.
    Ekins S; Williams AJ; Krasowski MD; Freundlich JS
    Drug Discov Today; 2011 Apr; 16(7-8):298-310. PubMed ID: 21376136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cheminformatics approaches to analyze diversity in compound screening libraries.
    Akella LB; DeCaprio D
    Curr Opin Chem Biol; 2010 Jun; 14(3):325-30. PubMed ID: 20457001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding Hsp90 inhibitors by drug repurposing: the power of chemical genetics.
    Xiong M; Zhang HY
    Drug Discov Today; 2012 Jun; 17(11-12):531-3. PubMed ID: 22469949
    [No Abstract]   [Full Text] [Related]  

  • 18. Old friends in new guise: repositioning of known drugs with structural bioinformatics.
    Haupt VJ; Schroeder M
    Brief Bioinform; 2011 Jul; 12(4):312-26. PubMed ID: 21441562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mining small-molecule screens to repurpose drugs.
    Swamidass SJ
    Brief Bioinform; 2011 Jul; 12(4):327-35. PubMed ID: 21715466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling.
    Meslamani J; Li J; Sutter J; Stevens A; Bertrand HO; Rognan D
    J Chem Inf Model; 2012 Apr; 52(4):943-55. PubMed ID: 22480372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.